A phase I study of AT9283 given as a 24 hour infusion on days 1 and 8 every three weeks in patients with advanced incurable malignancy.

Trial Profile

A phase I study of AT9283 given as a 24 hour infusion on days 1 and 8 every three weeks in patients with advanced incurable malignancy.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs AT 9283 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Feb 2017 Results of population model of AT9283 developed from the data of phase I trials of AT9283 (NCT00443976, NCT00522990, NCT00985868 and NCT01431664) published in the British Journal of Clinical Pharmacology.
    • 12 Nov 2010 Results from this trial will be presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Astex Therapeutics media release.
    • 26 Nov 2009 Planned end date changed from 1 Aug 2009 to 24 Nov 2009 as reported by National Cancer Institute of Canada record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top